Capillary disorder inhibitor, capillary disorder improving agent, and capillary angiogenesis promoter

Abstract

One or more embodiments of the present invention provide a capillary blood vessel disorder inhibiting agent, a capillary blood vessel disorder ameliorating agent, a capillary angiogenesis accelerating agent, or a diabetes complication prophylactic or inhibiting agent, containing a microorganism as an active ingredient.　One or more embodiments of the present invention pertain to a capillary blood vessel disorder inhibiting agent, a capillary blood vessel disorder ameliorating agent, or a capillary angiogenesis accelerating agent, containing strain R30 of Enterococcus faecium (accession No. NITE BP-01362). Another one or more embodiments of the present invention pertain to a diabetes complication prophylactic or inhibiting agent that contains strain R30 of Enterococcus faecium.

Description

[Technical field]

[0001] One or more embodiments of the present invention relate to an agent for suppressing capillary vascular disorder, an agent for improving capillary vascular disorder, or an agent for promoting capillary angiogenesis. One or more embodiments of the present invention also relate to an agent for preventing or suppressing diabetic complications. [Background technology]

[0002] It is known that in diabetic patients, the production of advanced glycation end products and excessive increase in active oxygen due to an increase in blood glucose levels cause the microvascular network in tissues to degenerate, resulting in diabetic complications (capillary disease). Traditionally, it was thought that lowering blood glucose levels was essential to suppress or improve diabetic capillary disease.

[0003] For example, Patent Document 1 discloses a blood glucose level lowering agent and a diabetes treatment and prevention agent containing microorganisms such as Enterococcus feliscus as an active ingredient. Patent Document 2 discloses a blood pressure lowering agent and a blood glucose lowering agent containing lactic acid bacteria such as Enterococcus feliscus as an active ingredient.

[0004] Meanwhile, the present applicant has reported in Patent Document 3 that Enterococcus faecium R30 strain is a lactic acid bacterium having fatigue-relieving and blood flow-improving effects. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2005 / 077390 Brochure [Patent Document 2] Japanese Patent Application Publication No. 10-7577 [Patent Document 3] International Publication No. 2014 / 021205 Brochure Summary of the Invention [Problem to be solved by the invention]

[0006] If capillary disorders can be suppressed, it is expected that diabetic complications can be prevented or suppressed. However, Patent Document 1 and Patent Document 2 only describe the reduction or lowering of blood glucose levels, and do not describe the effect of directly suppressing or improving capillary disorders. Furthermore, Patent Document 3 only describes the blood flow improvement effect as the action of recovering blood flow that has decreased under low temperature conditions when returned to normal temperature conditions, and does not describe the effect of suppressing or improving capillary disorders.

[0007] Therefore, one or more embodiments of the present invention have an objective of providing a capillary disorder inhibitor, a capillary disorder ameliorator, a capillary angiogenesis promoter, and an agent for preventing or inhibiting diabetic complications, which contain a microorganism as an active ingredient. [Means for solving the problem]

[0008] As a result of intensive research by the present inventors to solve the above problems, they have completed the following invention. (1) A capillary disorder inhibitor containing Enterococcus faecium R30 strain (accession number NITE BP-01362). (2) A capillary disorder inhibitor according to (1) for suppressing diabetic capillary disorder. (3) A capillary disorder inhibitor according to (1) or (2), which contains killed bacteria of the strain. (4) A capillary disorder inhibitor according to any one of (1) to (3), in which the dosage of Enterococcus faecium R30 strain (accession number NITE BP-01362) is 0.001 mg / kg body weight or more and 1000 mg / kg body weight or less. (5) A capillary disorder inhibitor according to any one of (1) to (4), having a content of Enterococcus faecium R30 strain (accession number NITE BP-01362) of 0.001% by weight or more and 100% by weight or less. (6) An agent for improving capillary disorders, containing Enterococcus faecium strain R30 (accession number NITE BP-01362). (7) The agent for improving capillary disorder according to (6) for improving diabetic capillary disorder. (8) The agent for improving capillary disorders according to (6) or (7), which contains killed cells of the strain. (9) The agent for improving capillary disorders according to any one of (6) to (8), wherein the dosage of Enterococcus faecium R30 strain (accession number NITE BP-01362) is 0.001 mg / kg body weight or more and 1000 mg / kg body weight or less. (10) The agent for improving capillary disorders according to any one of (6) to (9), wherein the content of Enterococcus faecium R30 strain (accession number NITE BP-01362) is 0.001% by weight or more and 100% by weight or less. (11) A capillary angiogenesis promoter containing Enterococcus faecium strain R30 (accession number NITE BP-01362). (12) The capillary angiogenesis promoter according to (11) for improving or suppressing diabetic capillary disorders. (13) The capillary angiogenesis promoter according to (11) or (12), which contains killed cells of the strain. (14) The capillary angiogenesis promoter according to any one of (11) to (13), wherein the dosage of Enterococcus faecium R30 strain (accession number NITE BP-01362) is 0.001 mg / kg body weight or more and 1000 mg / kg body weight or less. (15) The capillary angiogenesis promoter according to any one of (11) to (14), wherein the content of Enterococcus faecium R30 strain (accession number NITE BP-01362) is 0.001% by weight or more and 100% by weight or less. (16) A preventive or suppressive agent for diabetic complications containing Enterococcus faecium R30 strain (accession number NITE BP-01362). (17) An agent for preventing or suppressing diabetic complications according to (16), comprising killed cells of the strain. (18) Use of Enterococcus faecium R30 strain in the production of a capillary disorder inhibitor. (19) Use of Enterococcus faecium R30 strain in the manufacture of an agent for improving capillary disorders. (20) Use of Enterococcus faecium R30 strain in the production of a capillary angiogenesis promoter. (21) Use of Enterococcus faecium R30 strain in the manufacture of an agent for preventing or suppressing diabetic complications. (22) A method for suppressing capillary disorders, comprising administering an effective amount of Enterococcus faecium R30 strain to a patient. (23) The method for suppressing diabetic capillary disease described in (22), wherein the patient is a patient in need of suppression of diabetic capillary disease. (24) A method for improving capillary disorders, comprising administering to a patient an effective amount of Enterococcus faecium R30 strain. (25) The method for improving diabetic capillary disease described in (24), wherein the patient is a patient in need of improvement of diabetic capillary disease. (26) A method for promoting capillary angiogenesis, comprising administering an effective amount of Enterococcus faecium R30 strain to a patient. (27) The method for promoting capillary angiogenesis according to (26), wherein the patient is a patient in need of promotion of capillary angiogenesis. (28) A method for preventing or suppressing diabetic complications, comprising administering an effective amount of Enterococcus faecium R30 strain to a patient in need of such prevention or suppression. (29) Use of Enterococcus faecium R30 strain for inhibiting capillary disorder. (30) Use of (29), comprising administering an effective amount of Enterococcus faecium R30 strain to a patient in need of inhibition of capillary disorder. (31) Use of Enterococcus faecium R30 strain for improving capillary disorders. (32) Use of (31), comprising administering an effective amount of Enterococcus faecium R30 strain to a patient in need of improvement of capillary disorder. (33) Use of Enterococcus faecium R30 strain for promoting capillary angiogenesis. (34) Use of (33), comprising administering an effective amount of Enterococcus faecium R30 strain to a patient in need of promoting capillary angiogenesis. (35) Use of Enterococcus faecium R30 strain for the prevention or suppression of diabetic complications. (36) Use of (35), comprising administering an effective amount of Enterococcus faecium R30 strain to a patient in need of prevention or suppression of diabetic complications. (37) The use according to any one of (29) to (36), which is for non-medical use. (38) The use according to any one of (29) to (36), which is for medical use. (39) Enterococcus faecium R30 strain for use in a method for inhibiting capillary obstruction. (40) The Enterococcus faecium R30 strain according to (39), wherein the method comprises administering an effective amount of the Enterococcus faecium R30 strain to a patient in need of suppression of capillary disorder. (41) Enterococcus faecium R30 strain for use in a method for improving capillary dysfunction. (42) The Enterococcus faecium R30 strain according to (41), wherein the method comprises administering an effective amount of the Enterococcus faecium R30 strain to a patient in need of improvement of capillary disorders. (43) Enterococcus faecium strain R30 for use in a method for promoting capillary angiogenesis. (44) The Enterococcus faecium R30 strain according to (43), wherein the method comprises administering an effective amount of the Enterococcus faecium R30 strain to a patient in need of promoting capillary angiogenesis. (45) Enterococcus faecium R30 strain for use in a method for preventing or suppressing diabetic complications. (46) The Enterococcus faecium R30 strain according to (45), wherein the method comprises administering an effective amount of the Enterococcus faecium R30 strain to a patient in need of prevention or suppression of diabetic complications.

[0009] This specification includes the disclosures of Japanese Patent Application No. 2019-239057 and Japanese Patent Application No. 2020-091420, which are priority documents of this application. Effect of the Invention

[0010] The capillary disorder inhibitor according to one or more embodiments of the present invention has an excellent effect of inhibiting capillary disorder. The capillary disorder improving agent or capillary angiogenesis promoter according to the present invention has an excellent effect of improving capillary disorder or promoting angiogenesis. The capillary disorder inhibitor or improving agent or capillary angiogenesis promoter according to one or more embodiments of the present invention is effective in inhibiting or improving, for example, diabetic muscle tissue capillary disorder.

[0011] The prophylactic or suppressive agent for diabetic complications according to one or more embodiments of the present invention can prevent or suppress diabetic complications by suppressing or improving capillary disorders that cause diabetic complications or promoting capillary angiogenesis. The prophylactic or suppressive agent for diabetic complications according to one or more embodiments of the present invention can prevent or suppress diabetic complications by an action different from that of diabetes treatment drugs that have a blood glucose level lowering action. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 shows the results of blood glucose level measurements taken in Example 2 for the Wistar rat / saline-administered group (CON / Saline: n=6), the Wistar rat / Enterococcus faecium R30-administered group (CON / R30: n=7), the GK rat / saline-administered group (GK / Saline: n=6), and the GK rat / Enterococcus faecium R30-administered group (GK / R30: n=6), immediately after glucose loading (0 min), and 15, 30, 60, and 120 min after glucose loading. [Diagram 2] Figure 2 shows the results of measuring the capillary diameter in the soleus muscle after 8 weeks of breeding in the Wistar rat / saline administration group (CON / Saline), Wistar rat / Enterococcus faecium R30 administration group (CON / R30), GK rat / saline administration group (GK / Saline), and GK rat / Enterococcus faecium R30 administration group (GK / R30) in Example 3. *p<0.05 vs.CON / Saline, #p<0.05 vs.GK / Saline [Diagram 3]Figure 3 shows three-dimensional images of capillaries constructed using a confocal laser microscope and fluorescence imaging software from longitudinal sections of soleus muscles of the GK rat / saline-administered group (GK / Saline) and the GK rat / Enterococcus faecium R30-administered group (GK / R30) after 8 weeks of breeding in Example 4. [Figure 4] FIG. 4 shows the results of measuring the amount of biosynthesis of the angiogenesis inhibitor TSP-1 in the soleus muscle after 8 weeks of feeding in the Wistar rat / saline-administered group (CON / Saline), Wistar rat / Enterococcus faecium R30-administered group (CON / R30), GK rat / saline-administered group (GK / Saline), and GK rat / Enterococcus faecium R30-administered group (GK / R30) in Example 5. *p<0.05 vs.CON / Saline [Diagram 5] Figure 5 shows the results of measuring the amount of VEGF biosynthesis, which is involved in capillary angiogenesis, in the soleus muscle of Wistar rats / saline administration group (CON / Saline), Wistar rats / Enterococcus faecium R30 administration group (CON / R30), GK rats / saline administration group (GK / Saline), and GK rats / Enterococcus faecium R30 administration group (GK / R30) after 8 weeks of feeding in Example 5. *p<0.05 vs.CON / Saline, #p<0.05 vs.GK / Saline DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] <Enterococcus faecium R30 strain> The capillary disorder inhibitor, ameliorator, and capillary angiogenesis promoter as well as the preventive or inhibitor of diabetic complications according to one or more embodiments of the present invention are characterized in that they contain Enterococcus faecium R30 strain as an active ingredient. Hereinafter, Enterococcus faecium R30 strain may be abbreviated simply as "R30 strain."

[0014] Enterococcus faecium R30 strain has been deposited at the depository institution as follows: (i) The name and address of the depositary institution; Name: National Institute of Technology and Evaluation, Patent Microorganism Deposit Center Address: Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (ii) Domestic acceptance date: May 16, 2012 (iii) Date of receipt of request for transfer to international deposit: April 24, 2013 (iv) Accession number: NITE BP-01362 Enterococcus faecium strain R30 has the following mycological properties:

[0015] [Table 1]

[0016] The method for culturing the R30 strain used in one or more embodiments of the present invention is not particularly limited as long as it can effectively culture the R30 strain. For example, the R30 strain can be cultured by test tube culture, flask culture, fermenter culture, etc. The medium is also not particularly limited, and any medium can be used as long as it can effectively culture the R30 strain. For example, MRS medium, which is commonly used for culturing lactic acid bacteria, can be used.

[0017] The R30 strain used in one or more embodiments of the present invention may be a live or killed (killed and sterilized) bacteria.

[0018] A viable bacterium is a living R30 strain, and includes not only those that are capable of multiplying, but also those that are not multiplying and are in a dormant state but can grow again in the presence of water, etc.

[0019] Killed bacteria (killed sterilization) refers to bacteria that have been sterilized by heating, pressurization, drug treatment, or the like. The sterilization method is not particularly limited, and examples thereof include dry heat sterilization, steam sterilization, high-pressure steam sterilization, chemical sterilization, ultrasonic sterilization, electromagnetic wave sterilization, and ultraviolet sterilization. Sterilization may be performed after drying the collected bacteria. The killed bacteria may be the killed bacteria themselves or a processed product. Examples of the "processed product" include products that have been subjected to at least one process selected from grinding or crushing bacteria, concentration, pasting, drying, and dilution. The drying method for bacteria is not particularly limited, and examples thereof include spray drying, freeze drying, vacuum drying, and drum drying.

[0020] <Capillary disorder inhibitor> One or more embodiments of the present invention relate to a capillary disorder inhibitor containing the R30 strain. One or more further embodiments of the present invention relate to the use of the R30 strain in the production of a capillary disorder inhibitor.

[0021] The capillary disorder inhibitor may be a food or drink composition ingested for non-medical purposes, a pharmaceutical composition ingested for medical purposes, or a feed composition. Specific examples of the food or drink composition, pharmaceutical composition, or feed composition are described below. The pharmaceutical composition may be a pharmaceutical composition for humans or a pharmaceutical composition for non-human animals, but is preferably a pharmaceutical composition for humans.

[0022] One or more further embodiments of the present invention are directed to a method for inhibiting capillary disease, comprising administering to a patient an effective amount of Enterococcus faecium strain R30.

[0023] Another embodiment of the present invention is the use of Enterococcus faecium R30 strain for inhibiting capillary disorder.

[0024] One or more further embodiments of the present invention are Enterococcus faecium strain R30 for use in a method for inhibiting capillary disease.

[0025] The R30 strain used in each of the above embodiments can be in the various forms described above.

[0026] The capillary disorder inhibitor according to one or more embodiments of the present invention has an excellent effect of inhibiting capillary disorder. The capillary disorder inhibitor according to one or more embodiments of the present invention is effective in inhibiting, for example, diabetic muscle capillary disorder.

[0027] In the present disclosure, capillary disorder refers to a disorder in which capillaries in tissues regress. Therefore, the term "capillary disorder" is synonymous with "capillary regression" or "tissue capillary regression." Capillary disorders are typically diabetic capillary disorders, but may be capillary disorders caused by other factors. Diabetic capillary disorders are disorders of the microcapillary network in tissues that occur due to the production of advanced glycation end products and an increase in excessive reactive oxygen species associated with an increase in blood glucose levels, and are the cause of diabetic complications.

[0028] Conventionally, it was thought that controlling blood glucose level was essential for suppressing diabetic tissue capillary disorder. In contrast, the capillary disorder inhibitor according to one or more embodiments of the present invention is characterized by suppressing tissue capillary disorder without suppressing the rise in blood glucose level. Therefore, when the capillary disorder inhibitor according to one or more embodiments of the present invention is administered in combination with a drug having an effect of suppressing blood glucose level to a patient suffering from diabetes and diabetic complications, it is preferable because the dose of the drug having an effect of suppressing blood glucose level can be reduced. If the dose of the drug having an effect of suppressing blood glucose level can be reduced, it is useful in reducing unwanted side effects of the drug and reducing medical expenses. In addition, if a patient stops administering a drug having an effect of suppressing blood glucose level due to side effects, capillary disorder progresses over time, blood is not transported to the extremities, and in the worst case, it leads to necrosis of the extremities. However, the capillary disorder inhibitor according to one or more embodiments of the present invention can suppress capillary disorder without administering a drug having an effect of suppressing blood glucose level. In other words, the capillary disorder inhibitor according to one or more embodiments of the present invention can be administered to patients who have side effects from drugs that have the effect of suppressing blood glucose levels, and is useful because there is no need to limit the patients to whom the inhibitor can be administered.

[0029] Furthermore, the administration of the capillary disorder inhibitor according to one or more embodiments of the present invention to a patient can be performed in combination with exercise therapy for the patient.

[0030] The patient referred to in "administration to a patient" may be any patient who requires inhibition of capillary disorders, as described below. This includes not only patients with capillary disorders, but also those who have not yet manifested symptoms of capillary disorders but who may develop or manifest symptoms of capillary disorders in the future, and those who need or want to prevent capillary disorders.

[0031] The effect of suppressing capillary disorders can be evaluated, for example, by measuring the capillary diameter in the soleus muscle of Goto-Kakizaki (GK) rats, which are a model of spontaneous type 2 diabetes. If the soleus muscle capillary diameter of GK rats administered with the test substance is larger than that of experimental animals not administered with the test substance, the test substance can be evaluated as having an effect of suppressing capillary disorders. The suppression effect can also be evaluated by visually observing images of fluorescently stained capillaries in the soleus muscle of the rats. If an image showing larger capillaries in GK rats administered with the test substance can be observed compared to experimental animals not administered with the test substance, the test substance can be evaluated as having an effect of suppressing capillary disorders.

[0032] The frequency and dosage of administration of the capillary vascular disorder inhibitor according to one or more embodiments of the present invention to a patient may be appropriately adjusted according to the age, sex, condition, etc. of the patient to be administered. The daily dosage of the R30 strain may be appropriately adjusted, and may be, for example, 0.001 mg / kg body weight or more and 1000 mg / kg body weight or less. The dosage is preferably 0.01 mg / kg body weight or more, more preferably 0.1 mg / kg body weight or more, more preferably 10 mg / kg body weight or more, preferably 800 mg / kg body weight or less, and more preferably 550 mg / kg body weight or less. The number of times of administration per day may also be appropriately adjusted, and may be, for example, 1 time or more and 5 times or less. The route of administration may be oral administration or parenteral administration, and is preferably oral administration. The patient to be administered may be any patient who requires inhibition of capillary vascular disorder, and may be, for example, a human or a non-human animal, and preferably a human. Examples of non-human animals include farmed animals, pet animals, and sports animals. Examples of farmed animals include, but are not limited to, livestock animals such as horses, cows, pigs, sheep, goats, camels, and llamas; laboratory animals such as mice, rats, guinea pigs, and rabbits; and poultry such as chickens, ducks, turkeys, and ostriches. Examples of pet animals include, but are not limited to, dogs and cats. Examples of sports animals include, but are not limited to, race horses. It is particularly preferred that the non-human animal is a mammal.

[0033] The capillary disorder inhibitor according to one or more embodiments of the present invention may contain various additives such as excipients. Specific examples of the various additives will be described later. In addition, the content of the R30 strain in the capillary disorder inhibitor when the capillary disorder inhibitor contains the various additives is not particularly limited, but the lower limit is preferably 0.001% by weight or more, for example, 0.01% by weight or more, more preferably 0.1% by weight or more. In addition, the upper limit is preferably 100% by weight or less, for example, 50% by weight or less, more preferably 30% by weight or less.

[0034] In addition, when the capillary vessel inhibitor according to one or more embodiments of the present invention is in the form of a preparation such as a capsule or tablet, the content of the R30 strain contained in one preparation is not particularly limited and may be appropriately adjusted, but may be, for example, 0.1 mg / formulation or more and 1000 mg / formulation or less. The content of the R30 strain contained in one preparation is preferably 5 mg / formulation, 10 mg / formulation, 30 mg / formulation, 50 mg / formulation, or 100 mg / formulation.

[0035] When the capillary vascular disorder inhibitor according to one or more embodiments of the present invention is a food or drink composition, a pharmaceutical composition, or a feed composition, or when the capillary vascular disorder inhibitor according to one or more embodiments of the present invention is used in the production of a food or drink composition, a pharmaceutical composition, or a feed composition, the content of the R30 strain in the food or drink composition, pharmaceutical composition, or feed composition produced is not particularly limited and may be appropriately adjusted, but for example, the content in the food or drink composition, pharmaceutical composition, or feed composition may be 0.00001% by weight or more as a lower limit. The lower limit is, for example, 0.001% by weight or more, preferably 0.01% by weight or more. The upper limit may be 90% by weight or less. The upper limit is preferably 80% by weight or less, 70% by weight or less, 60% by weight or less, or 50% by weight or less. More preferably, 30% by weight or less is preferable.

[0036] <Capillary disorder improving agent> One or more embodiments of the present invention relate to an agent for improving capillary disorders, comprising the R30 strain. One or more further embodiments of the present invention relate to use of the R30 strain in the production of an agent for improving capillary disorder.

[0037] The capillary disorder improving agent may be a food or drink composition ingested for non-medical purposes, a pharmaceutical composition ingested for medical purposes, or a feed composition, similar to the above-mentioned capillary disorder inhibitor. Specific examples of the food or drink composition, pharmaceutical composition, or feed composition are described below. The pharmaceutical composition may be a pharmaceutical composition for humans or a pharmaceutical composition for non-human animals, but is preferably a pharmaceutical composition for humans.

[0038] One or more further embodiments of the present invention are directed to a method for improving capillary disorders, comprising administering to a patient an effective amount of Enterococcus faecium strain R30.

[0039] Another embodiment of the present invention is the use of Enterococcus faecium R30 strain for improving capillary disorders.

[0040] Another embodiment of the present invention is Enterococcus faecium strain R30 for use in a method for ameliorating capillary dysfunction.

[0041] The R30 strain used in each of the above embodiments can be in the various forms described above.

[0042] The agent for improving capillary disorder according to one or more embodiments of the present invention is effective in improving diabetic capillary disorder in muscle tissue, for example.

[0043] The capillary disorder improving agent according to one or more embodiments of the present invention can improve capillary disorder caused by an increase in blood glucose level without taking a diabetes drug having an effect of suppressing blood glucose level. Therefore, the capillary disorder improving agent according to one or more embodiments of the present invention is preferable when used in combination with a diabetes drug having an effect of suppressing blood glucose level, because the intake amount can be reduced. In addition, the capillary disorder improving agent is useful because it can be administered to patients who have stopped taking a diabetes drug due to side effects.

[0044] Furthermore, the administration of the capillary disorder improving agent according to one or more embodiments of the present invention to a patient can be performed in combination with exercise therapy for the patient.

[0045] The patient referred to in "administration to a patient" may be any patient who requires improvement of capillary disorder, and includes not only patients with capillary disorder, but also those who have not yet manifested symptoms of capillary disorder but who may develop or manifest symptoms of capillary disorder in the future, and those who need to prevent or want to prevent capillary disorder.

[0046] The improving effect of capillary disorders can be evaluated, for example, by measuring the capillary diameter in the soleus muscle of Goto-Kakizaki (GK) rats, which are a model of spontaneous type 2 diabetes. If the soleus muscle capillary diameter of GK rats administered with the test substance is larger than that of experimental animals not administered with the test substance, the test substance can be evaluated as having a capillary improving effect. The improving effect can also be evaluated by visually observing images of fluorescently stained capillaries in the soleus muscle of the rats. If an image showing larger capillaries in GK rats administered with the test substance can be observed compared to experimental animals not administered with the test substance, the test substance can be evaluated as having a capillary improving effect.

[0047] The frequency and dosage of administration to a patient of the capillary disorder improving agent according to one or more embodiments of the present invention can be selected from the examples described above for the capillary disorder inhibitor.

[0048] When the capillary disorder improving agent according to one or more embodiments of the present invention is a food or beverage composition, a pharmaceutical composition, or a feed composition, or when the capillary disorder improving agent according to one or more embodiments of the present invention is used in the manufacture of a food or beverage composition, a pharmaceutical composition, or a feed composition, the content of the R30 strain in the food or beverage composition, pharmaceutical composition, or feed composition; and when the capillary disorder improving agent according to one or more embodiments of the present invention is in the form of a formulation such as a capsule or tablet, the content of the R30 strain contained per formulation can be selected from the examples described above for capillary disorder inhibitors.

[0049] <Capillary angiogenesis promoter> One or more embodiments of the present invention relate to a capillary angiogenesis promoter comprising the R30 strain. One or more further embodiments of the present invention relate to the use of the R30 strain in the production of a capillary angiogenesis promoter.

[0050] The capillary angiogenesis promoter may be a food or drink composition ingested for non-medical purposes, a pharmaceutical composition ingested for medical purposes, or a feed composition, similar to the above-mentioned capillary disorder inhibitor and capillary disorder ameliorator. Specific examples of food or drink compositions, pharmaceutical compositions, and feed compositions are described below. The pharmaceutical composition may be a human pharmaceutical composition or a non-human animal pharmaceutical composition, but is preferably a human pharmaceutical composition.

[0051] One or more further embodiments of the present invention are directed to a method of promoting capillary angiogenesis comprising administering to a patient an effective amount of Enterococcus faecium strain R30.

[0052] Another embodiment of the present invention is the use of Enterococcus faecium strain R30 for promoting capillary angiogenesis.

[0053] Another embodiment of the present invention is Enterococcus faecium strain R30 for use in a method for promoting capillary angiogenesis.

[0054] The R30 strain used in each of the above embodiments can be in the various forms described above.

[0055] The capillary angiogenesis promoter according to the present invention is effective, for example, in improving or suppressing diabetic capillary disorder in muscle tissue.

[0056] The capillary angiogenesis promoter according to one or more embodiments of the present invention can promote angiogenesis and improve capillary disorders such as capillary regression. Furthermore, the capillary angiogenesis promoter according to one or more embodiments of the present invention can be administered to a patient in combination with exercise therapy for the patient.

[0057] The patient referred to in "administration to a patient" may be any patient who requires the regeneration of capillaries, and includes not only patients with capillary disorders, but also those who have not yet manifested symptoms of capillary disorders but who may develop or manifest symptoms in the future, and those who need or want to prevent capillary disorders.

[0058] The capillary angiogenesis promoting effect can be evaluated, for example, by measuring the capillary diameter in the soleus muscle of Goto-Kakizaki (GK) rats, which are a model of spontaneous type 2 diabetes. If the soleus muscle capillary diameter of GK rats administered with the test substance is larger than that of experimental animals not administered with the test substance, the test substance can be evaluated as having a capillary angiogenesis promoting effect. The promoting effect can also be evaluated by visually observing an image of the fluorescently stained capillaries in the soleus muscle of the rat. If an image showing larger capillaries in GK rats administered with the test substance can be observed compared to experimental animals not administered with the test substance, the test substance can be evaluated as having a capillary angiogenesis promoting effect.

[0059] The frequency and dosage of administration to a patient of the capillary angiogenesis promoter according to one or more embodiments of the present invention can be selected from the examples given above for the capillary disorder inhibitor and capillary improvement agent.

[0060] When the capillary angiogenesis-promoting agent according to one or more embodiments of the present invention is a food or beverage composition, a pharmaceutical composition, or a feed composition, or when the capillary angiogenesis-promoting agent according to one or more embodiments of the present invention is used in the manufacture of a food or beverage composition, a pharmaceutical composition, or a feed composition, the content of the R30 strain in the food or beverage composition, a pharmaceutical composition, or a feed composition; and when the capillary angiogenesis-promoting agent according to one or more embodiments of the present invention is in the form of a formulation such as a capsule or tablet, the content of the R30 strain contained per formulation can be selected from the examples described above for capillary disorder inhibitors.

[0061] <Agents for preventing or suppressing diabetic complications> One or more embodiments of the present invention relate to an agent for preventing or suppressing diabetic complications comprising the R30 strain. One or more further embodiments of the present invention relate to the use of the R30 strain in the manufacture of an agent for the prevention or suppression of diabetic complications.

[0062] The food and drink composition for preventing or suppressing diabetic complications may be a food and drink composition ingested for non-medical purposes, a food and drink composition ingested for medical purposes, or a feed composition. Specific examples of the food and drink composition, pharmaceutical composition, or feed composition are as described below. The pharmaceutical composition may be a pharmaceutical composition for humans or a pharmaceutical composition for non-human animals, but is preferably a pharmaceutical composition for humans.

[0063] One or more further embodiments of the present invention are methods for preventing or suppressing diabetic complications, comprising administering an effective amount of the R30 strain to a patient in need thereof.

[0064] Another embodiment of the present invention is the use of Enterococcus faecium strain R30 for the prevention or inhibition of diabetic complications.

[0065] One or more further embodiments of the present invention are Enterococcus faecium strain R30 for use in a method for preventing or inhibiting diabetic complications.

[0066] The R30 strain used in each of the above embodiments can be in the various forms described above.

[0067] In each of the above embodiments, prevention of diabetic complications refers to preventing the onset or contraction of diabetic complications, and suppression of diabetic complications refers to suppressing the progression of diabetic complications.

[0068] The prophylactic or suppressive agent for diabetic complications according to one or more embodiments of the present invention can prevent or suppress diabetic complications by suppressing capillary disorders that cause diabetic complications. The targeted diabetic complications may be complications of type 1 diabetes or complications of type 2 diabetes.

[0069] When the preventive or suppressive agent for diabetic complications according to one or more embodiments of the present invention is administered in combination with a diabetic drug having an effect of suppressing blood glucose level to a patient suffering from diabetes and diabetic complications, it is preferable because the dose of the diabetic drug can be reduced. In addition, the preventive or suppressive agent for diabetic complications according to one or more embodiments of the present invention is also effective for patients who have stopped administering a diabetic drug having an effect of suppressing blood glucose level due to side effects. The administration of the agent for preventing or suppressing diabetic complications according to one or more embodiments of the present invention to a patient can be performed in combination with an exercise therapy for the patient.

[0070] The frequency and dosage of administration of the preventive or suppressive agent for diabetic complications according to one or more embodiments of the present invention to a patient who needs to prevent or suppress diabetic complications may be appropriately adjusted according to the age, sex, condition, etc. of the patient to be administered. The daily dosage of the R30 strain may be appropriately adjusted, and may be, for example, 0.001 mg / kg body weight or more and 1000 mg / kg body weight or less. The dosage is preferably 0.01 mg / kg body weight or more, more preferably 0.1 mg / kg body weight or more, more preferably 10 mg / kg body weight or more, preferably 800 mg / kg body weight or less, and more preferably 550 mg / kg body weight or less. The number of times of administration per day may also be appropriately adjusted, and may be, for example, 1 time or more and 5 times or less. The route of administration may be oral administration or parenteral administration, and is preferably oral administration. The patient to be administered may be any patient who needs to suppress capillary disorders, and may be, for example, a human or a non-human animal, and preferably a human. Examples of non-human animals are as described above.

[0071] When the preventive or suppressive agent for diabetic complications according to one or more embodiments of the present invention is a food composition, a pharmaceutical composition, or a feed composition, or when the preventive or suppressive agent for diabetic complications according to one or more embodiments of the present invention is used in the manufacture of a food composition, a pharmaceutical composition, or a feed composition, the content of the R30 strain in the food composition, the pharmaceutical composition, or the feed composition is not particularly limited and may be appropriately adjusted, but for example, the content in the food composition, the pharmaceutical composition, or the feed composition may be 0.00001% by weight or more and 50% by weight or less. The proportion is preferably 0.001% by weight or more, more preferably 0.01% by weight or more, and preferably 30% by weight or less.

[0072] <Composition> The form of the capillary disorder inhibitor, capillary disorder improving agent, capillary angiogenesis promoter, or diabetic complication preventive or suppressive agent according to one or more embodiments of the present invention is not particularly limited. For example, it may be the R30 strain itself in the various forms described above, or a composition containing the R30 strain and other components. The composition containing the R30 strain and other components may be a composition according to the purpose, such as a pharmaceutical composition, a food and drink composition, or a feed composition.

[0073] The capillary disorder inhibitor, capillary disorder improving agent, capillary angiogenesis promoter, or agent for preventing or suppressing diabetic complications according to one or more embodiments of the present invention exhibits high efficacy when administered orally as shown in the examples described below, and is preferably a pharmaceutical composition, food and drink composition, or feed composition that is orally ingested or administered, in view of ease of ingestion and administration. Hereinafter, the "capillary disorder inhibitor, capillary disorder improving agent, capillary angiogenesis promoter, or agent for preventing or suppressing diabetic complications" according to one or more embodiments of the present invention may be simply referred to as "an agent according to one or more embodiments of the present invention."

[0074] For example, a composition containing live bacteria of the R30 strain can be produced by collecting the R30 strain cells in a culture medium cultured by a conventional method, adding a solution in which a protective agent is dissolved to the collected cells, drying them, and then mixing them with a suitable excipient. The protective agent refers to a component that protects the cells from the external environment and maintains the number of live bacteria or suppresses a decrease in the number of live bacteria. The protective agent may be, for example, trehalose, bovine serum albumin, skim milk powder, sodium glutamate, L-ascorbic acid, histidine, malic acid, whey, glucose, aspartic acid, methionine, starch, dextrin, sucrose, lactose, sodium chloride, phosphate, or other substances that can reduce damage to the cells. These protective agents can be used alone or in combination. The blending ratio of each protective agent is not limited, but the lower limit of the total amount of the protective agent is preferably 1% by weight or more based on the dry cell weight. If the ratio is 1% by weight or more, damage to the cells can be more reliably reduced. On the other hand, the upper limit of the ratio is not particularly limited, but can be, for example, 50,000% by weight or less. The ratio is preferably 10% by weight or more, more preferably 50% by weight or more, even more preferably 100% by weight or more, and more preferably 20,000% by weight or less, and even more preferably 10,000% by weight or less.

[0075] A composition containing killed cells of the R30 strain can be produced, for example, by harvesting cells in a culture medium cultured by a conventional method, sterilizing the harvested cells, drying them, and then mixing them with a suitable excipient.

[0076] In addition, the capillary disorder inhibitor, capillary disorder ameliorator, capillary angiogenesis promoter, or diabetic complication preventive or inhibitor according to one or more embodiments of the present invention may contain appropriate amounts of various additives used in the manufacture of general preparations, such as excipients, binders, disintegrants, acidulants, foaming agents, artificial sweeteners, flavors, lubricants, colorants, stabilizers, pH adjusters, surfactants, etc.

[0077] Examples of excipients include starches such as corn starch, potato starch, wheat cornstarch, rice starch, partially pregelatinized starch, pregelatinized starch, and porous starch; sugars such as lactose, sucrose, and glucose; sugar alcohols such as mannitol, xylitol, erythritol, sorbitol, and maltitol; and inorganic compounds such as magnesium aluminometasilicate, hydrotalcite, anhydrous calcium phosphate, precipitated calcium carbonate, calcium silicate, and light anhydrous silicic acid.

[0078] The excipients may further include, for example, gum arabic, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talc, colloidal silicon dioxide, and the like.

[0079] Examples of the binder include hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, powdered gum arabic, gelatin, and pullulan.

[0080] Examples of disintegrants include starch, agar, carmellose calcium, sodium carboxymethylstarch, croscarmellose sodium, crospovidone, crystalline cellulose, F-MELT (trademark, manufactured by Fuji Chemical Industry Co., Ltd.), and the like.

[0081] Examples of the acidulant include citric acid, tartaric acid, malic acid, ascorbic acid, etc. Examples of the foaming agent include sodium bicarbonate, sodium carbonate, etc. Examples of sweeteners include sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia, and thaumatin. Flavoring agents include, for example, lemon oil, orange oil, menthol, and the like.

[0082] Examples of lubricants include magnesium stearate, sucrose fatty acid esters, polyethylene glycol, talc, stearic acid, sodium stearyl fumarate, etc. Examples of colorants include food dyes such as Food Yellow No. 5, Food Red No. 2, Food Blue No. 2, food lake dyes, and ferric oxide.

[0083] Stabilizers include sodium edetate, tocopherol, cyclodextrin, and the like.

[0084] Examples of pH adjusters include citrates, phosphates, carbonates, tartrates, fumarates, acetates, and amino acid salts.

[0085] Surfactants include polysorbate 80, methylcellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, polyoxyethylene sorbitan monolaurate, gum arabic, powdered tragacanth, and the like.

[0086] Hereinafter, specific embodiments in which the agent according to one or more embodiments of the present invention is a pharmaceutical composition, a food or drink composition, or a feed composition will be described.

[0087] The agent containing the R30 strain according to one or more embodiments of the present invention can be a pharmaceutical composition. The pharmaceutical composition can be in the form of tablets, powders, capsules, sugar-coated tablets, granules, extracts, elixirs, syrups, tinctures, lemonades, etc. The pharmaceutical composition can contain medicamentously acceptable additives (also called pharma- ceutically acceptable carriers) according to the desired dosage form. Examples of such additives include excipients, disintegrants, lubricants, antioxidants, flavorings, seasonings, sweeteners, colorants, thickening stabilizers, colorants, bleaching agents, fungicides, gum bases, bittering agents, enzymes, glossing agents, acidulants, emulsifiers, strengtheners, manufacturing agents, binders, isotonicity agents, buffers, solubilizers, preservatives, stabilizers, anti-aggregating agents, absorption enhancers, coagulants, etc. The pharmaceutical composition can be manufactured by a conventional method according to the dosage form, etc.

[0088] The pharmaceutical composition may be a pharmaceutical composition administered to humans or a pharmaceutical composition administered to non-human animals. Specific examples of non-human animals are as described above. The pharmaceutical composition administered to non-human animals may be a composition containing, in addition to the R30 strain as an active ingredient, a component acceptable as a feed that can be incorporated into a feed composition described below.

[0089] The agent containing the R30 strain according to one or more embodiments of the present invention can be used as a food and drink composition. The food and drink composition may be a general food and drink composition such as a general food or drink or may be a food and drink composition for use as a so-called health food, supplement, functional food, functional food, nutritional supplement, food for specified health uses, nutritional functional food, health functional food, food for specified uses, nursing care food, smile care food, chewing and swallowing supplement, thick liquid food, food for sick people, dietary supplement, etc. The food and drink composition as the agent according to one or more embodiments of the present invention contains, in addition to the R30 strain, ingredients that are acceptable as food and drink.

[0090] The form of the food and drink composition is not particularly limited, and examples thereof include beverages such as milk drinks, soft drinks, sports drinks, nutritional drinks, beauty drinks, and liquid nutrients; confectioneries such as chewing gum, chocolate, candy, jelly, cake, pie, cookies, Japanese sweets, snacks, fried confectioneries, rice crackers, biscuits, and crackers; frozen desserts such as ice cream and frozen desserts; noodles such as udon, Chinese noodles, spaghetti, and instant noodles; paste products such as kamaboko, chikuwa, and half pieces; dressings, mayonnaise, and the like. Examples of typical food and drink compositions include condiments such as naise, sauces, and sauces; bread, ham, porridge, cooked rice, soup, retort foods, frozen foods, as well as edible oil and fat compositions, cooking oils, spray oils, butters, margarines, shortenings, whipped creams, concentrated milk, whiteners, dressings, pickle liquids, bakery mixes, fried foods, processed meat products, tofu, konjac, and other processed products; jams, fermented milk, canned foods, etc. The food and drink compositions may be fermented products obtained by fermenting a typical food and drink composition using the R30 strain.

[0091] When the food and drink composition is a food for specified health uses, a food with functional claims, or a dietary supplement, the food and drink composition may be packaged and the package may display functions related to the suppression of capillary disorders, the improvement of capillary disorders, the promotion of capillary angiogenesis, and the prevention or suppression of diabetic complications. The package is not particularly limited, but may be, for example, a box, a container, a packaging film, or a wrapping paper. In addition, the functions displayed on the package include the suppression of capillary disorders, the improvement of capillary disorders, the promotion of capillary angiogenesis, the prevention or suppression of diabetic complications, as well as functions related thereto, the suppression of capillary disorders, the improvement of capillary disorders, the promotion of capillary angiogenesis, and the prevention or suppression of diabetic complications, as described in this specification. Of course, as long as the functions are similar to these, the expressions may be different.

[0092] In addition, functional foods are foods that have vascular disorder inhibitor-like effects that are approved or designated by the government or public organizations, such as health functional foods such as nutrient functional foods and foods for specified health uses, foods for special dietary uses, etc. In addition, although names and regulations change depending on the situation and the times, foods that are essentially the same are included in the present invention.

[0093] The food and drink composition as an agent according to one or more embodiments of the present invention may be in the form of a capsule, syrup, tablet, pill, powder, granule, drink, injection, infusion, nasal drops, eye drops, suppository, patch, spray, etc. In the formulation, in addition to the R30 strain, other ingredients acceptable for food and drink, such as excipients, disintegrants, lubricants, binders, antioxidants, colorants, anti-aggregating agents, absorption promoters, solubilizers, stabilizers, etc., can be appropriately added to prepare the formulation.

[0094] The agent according to one or more embodiments of the present invention may be a feed composition (including pet food). The feed composition includes the R30 strain and ingredients acceptable as feed selected according to the breeding environment such as the type of animal, the development stage, and the region. Examples of ingredients acceptable as feed include general feed ingredients, feed additives normally used in compound feed (e.g., excipients, extenders, binders, thickeners, emulsifiers, colorants, flavorings, food additives, seasonings, etc.), and ingredients other than feed additives (e.g., antibiotics, bactericides, anthelmintics, preservatives, etc.). Examples of general feed ingredients include grains or processed grains, bran, vegetable oil cakes, animal ingredients, minerals, vitamins, amino acids, yeasts such as brewer's yeast, fine powders of inorganic substances, etc. Examples of grains or processed grains include corn, milo, barley, wheat, rye, oats, millet, wheat flour, wheat germ flour, etc. Examples of bran include wheat bran, rice bran, and corn gluten feed. Examples of vegetable oil cakes include soybean oil cake, sesame oil cake, cottonseed oil cake, peanut meal, sunflower meal, and safflower meal. Examples of animal raw materials include skim milk powder, fish meal, and meat and bone meal. Examples of minerals include calcium carbonate, calcium phosphate, salt, and anhydrous silicic acid. Examples of vitamins include vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, calcium pantothenate, nicotinamide, and folic acid. Examples of amino acids include glycine and methionine. Examples of inorganic fine powders include crystalline cellulose, talc, silica, muscovite, and zeolite.

[0095] The form of the feed composition is not particularly limited, and examples thereof include powder, granule, paste, pellet, capsule, tablet, etc. The capsule may be a hard capsule or a soft capsule. The non-human animal to which the feed composition is fed is not particularly limited. Specific examples of the non-human animal are as described above. EXAMPLES

[0096] Example 1: Preparation of freeze-dried Enterococcus faecium R30 cells MRS bouillon (Kanto Chemical) (0.52 g) was dissolved in water (10 mL), and then heat sterilized in an autoclave at 121°C for 15 minutes to prepare MRS liquid medium. A glycerol stock suspension (100 μL) of Enterococcus faecium R30 strain (accession number NITE BP-01362) was inoculated into the liquid medium (10 mL) and cultured at 37°C for 24 hours to obtain a preculture solution. The preculture solution (1 mL) was added to the above MRS liquid medium (100 mL), and cultured at 37°C for another 24 hours. After the culture was completed, the mixture was centrifuged at 8000 rpm for 10 minutes to separate the culture solution from the bacterial cells. The bacterial cells were washed with sterilized water (100 mL) and centrifuged again to separate the bacterial cells from the sterilized water. Sterile water (2 mL) was added to the cells, which were then sterilized by heating at 90°C for 30 minutes and then freeze-dried to obtain freeze-dried cells of Enterococcus faecium strain R30.

[0097] Example 2: Confirmation test of the effect of Enterococcus faecium R30 strain on blood glucose level Thirteen 5-week-old Wistar (CON) rats and 12 5-week-old male Goto-Kakizaki (GK) rats (type 2 diabetes model animals) were divided into Wistar rat / saline-administered group (CON / Saline: n=6), Wistar rat / Enterococcus faecium R30-administered group (CON / R30: n=7), GK rat / saline-administered group (GK / Saline: n=6), and GK rat / Enterococcus faecium R30-administered group (GK / R30: n=6). Each group was pre-bred for 1 week with normal food ("CE-2", CLEA Japan) and water ad libitum. Thereafter, the freeze-dried cells of the Enterococcus faecium R30 strain prepared in Example 1 above were dispersed in physiological saline, and the CON / R30 group and the GK / R30 group were orally administered the cells twice a day using a sonde (oral tube) so that the dose of the cells was 500 mg per kg of body weight, and the mice were kept for 8 weeks.

[0098] After 8 weeks of feeding, diabetes was evaluated by a glucose tolerance test. To evaluate diabetes, blood was collected after 18 hours of fasting (0 min), and 10 mL of glucose solution adjusted to 0.2 g / mL per kg of rat body weight (kg) was orally administered. Blood was collected 15, 30, 60, and 120 minutes later, and the blood glucose level in each blood sample was measured using a blood glucose meter (Precision Exceed, Abbott). The measurement results are shown in Figure 1.

[0099] As shown in the results in Figure 1, the increase in blood glucose level after glucose administration in the GK / Saline group, in which saline was administered to GK rats, a model of spontaneous type 2 diabetes, indicates that the GK rats are in a diabetic state. Similarly, the blood glucose level after glucose administration in the GK / R30 group, in which Enterococcus faecium R30 strain was administered to GK rats, also increased, indicating that the GK / R30 group was in a diabetic state.

[0100] On the other hand, blood glucose levels did not increase after glucose administration in the CON / Saline group, which were non-diabetic control Wistar rats administered saline, indicating that the CON / Saline group was not in a diabetic state, and that the CON / R30 group, in which Wistar rats were administered the Enterococcus faecium R30 strain, was also not in a diabetic state.

[0101] Example 3: Effect of Enterococcus faecium R30 strain on capillary diameter in soleus muscle After the glucose tolerance test after 8 weeks of feeding, each group in Example 2 was anesthetized with sodium pentobarbital (50 mg / kg), a cannula was inserted into the abdominal aorta, saline was perfused into the skeletal muscle capillaries, and a fluorescent contrast agent was perfused, which was an 8% gelatin solution (Sigma Aldrich) liquefied at 42°C and a 1% fluorescent substance (fluorescent marker refill ink, Tombow), and then the soleus muscle was excised. The excised soleus muscle was frozen at -80°C, and a longitudinal section of 100 μm was prepared using a cryostat, and then fixed with 4% paraformaldehyde. The capillaries present every 1 μm in the muscle section were scanned using a confocal laser microscope (C2+, NIKON) using an argon laser (488 nm) and fluorescence imaging software (NIS-Elements, NIKON), and the capillary diameter was measured. The measurement results are shown in Figure 2. The number of capillary diameter measurements (n) for the Wistar rat / saline-administered group (CON / Saline) was 29, the Wistar rat / Enterococcus faecium R30-administered group (CON / R30) was 29, the GK rat / saline-administered group (GK / Saline) was 27, and the GK rat / Enterococcus faecium R30-administered group (GK / R30) was 23.

[0102] As shown in Figure 2, the capillary diameter of the CON / Saline group (average 7.0 μm) was comparable to that of the CON / R30 group (average 7.2 μm). On the other hand, in the diabetic GK / Saline group, the capillary diameter was 6.0 μm, which is significantly smaller than that of the CON / Saline group, indicating that capillary damage was occurring due to the diabetic state. In contrast, the capillary diameter of the GK / R30 group was 7.0 μm, which is significantly larger than that of the GK / Saline group, indicating that the capillary diameter was equivalent to that of the non-diabetic CON / Saline group. These results demonstrated that Enterococcus faecium R30 lactobacillus has an inhibitory effect on capillary damage.

[0103] Example 4: Effect of Enterococcus faecium R30 strain on capillary angiogenesis in soleus muscle Six 5-week-old male Goto-Kakizaki (GK) rats (type 2 diabetes model animals) were divided into a GK rat / physiological saline administration group (GK / Saline: n=3) and a GK rat / Enterococcus faecium R30 administration group (GK / R30: n=3). Each group was pre-bred for one week with normal feed ("CE-2", CLEA Japan) and water ad libitum. Thereafter, the lyophilized Enterococcus faecium R30 strain prepared in Example 1 was dispersed in physiological saline, and the GK / R30 group was orally administered 500 mg of the bacteria per kg of body weight twice a day using a sonde (oral tube), and bred for 8 weeks. After 8 weeks of feeding, the rats were anesthetized with sodium pentobarbital (50 mg / kg), a cannula was inserted into the abdominal aorta, and the skeletal muscle capillaries were perfused with saline. After perfusion of a fluorescent contrast agent consisting of 8% gelatin solution (Sigma Aldrich) liquefied at 42°C and 1% fluorescent substance (Fluorescent Marker Refill Ink Tombow), the soleus muscle was excised. The excised soleus muscle was frozen at -80°C, cut into 100 μm-thick longitudinal sections using a cryostat, fixed in 4% paraformaldehyde, and scanned every 1 μm of the muscle section using a confocal laser microscope (C2+ NIKON) with an argon laser (488 nm) and fluorescence imaging software (NIS-Elements NIKON) to construct a 3D capillary image. Figure 3 shows a 3D image of the capillaries constructed using a confocal laser microscope and fluorescence imaging software.

[0104] As shown in Figure 3, the capillary diameter was reduced in the diabetic GK / Saline group, indicating that capillary damage was occurring due to the diabetic state. On the other hand, the GK / R30 group had more dense capillaries than the GK / Saline group, indicating that new capillaries were being formed. This demonstrated that Enterococcus faecium R30 lactobacillus has the effect of improving capillary damage and / or promoting capillary angiogenesis.

[0105] Example 5: Capillary angiogenesis confirmation test The soleus muscle excised in Example 3 and frozen at -80°C was homogenized in HEPES buffer supplemented with a protease inhibitor, and then centrifuged to recover the supernatant. The total protein amount in the supernatant was measured, and the concentration was adjusted so that the total protein amount between samples was the same, and then the supernatant was subjected to SDS-PAGE. The proteins developed by electrophoresis were transferred to a PVDF membrane, and after blocking, a 100-fold dilution of anti-thrombospondin-1 (TSP-1) antibody ("sc-59887" manufactured by Santa Cruz Biotechnology), a 200-fold dilution of anti-VEGF antibody ("sc-7269" manufactured by Santa Cruz Biotechnology), or a 200-fold dilution of anti-β-actin antibody ("sc-47778" manufactured by Santa Cruz Biotechnology) was added, incubated, and then an HRP-labeled secondary antibody was added, and color development was performed using an HRP detection reagent ("Easy West Lumi One" manufactured by ATTO). Images were captured using a luminometer image analyzer ("LAS-1000" Fujifilm), and the optical density was measured using image analysis software ("Science Lab" Fujifilm), to measure the biosynthesis levels of TSP-1, VEGF, and β-actin. The biosynthesis levels of TSP-1 and VEGF in each sample were normalized by the biosynthesis level of β-actin in the same sample, and normalized as relative values ​​to CON / Saline. One-way analysis of variance and Turkey-Kramer multiple comparison test were performed on the measured values. The results are shown in Figures 4 and 5. In Figures 4 and 5, "*" indicates a significant difference with the CON / Saline group at p<0.05, and "#" indicates a significant difference with the GK / Saline group at p<0.05. In Figures 4 and 5, the biosynthesis levels of TSP-1 and VEGF in each group are shown as relative values ​​when the biosynthesis levels of TSP-1 and VEGF in the CON / Saline group were set at 100.

[0106] As shown in Figure 4, both the GK / Saline group and the GK / R30 group had significantly higher expression levels of the angiogenesis inhibitor TSP-1 compared to the non-diabetic control rat CON / Saline group. In addition, as shown in Figure 5, the GK / R30 group had a significantly higher synthesis level of VEGF, which is involved in capillary angiogenesis, than the CON / Saline group and the GK / Saline group. This demonstrated that Enterococcus faecium R30 lactobacillus has a capillary angiogenesis-promoting effect in conditions where capillary disorders are occurring due to diabetes.

[0107] All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety.

Claims

1. A capillary disorder inhibitor for inhibiting diabetic capillary disorder, comprising Enterococcus faecium strain R30.

2. The capillary disorder inhibitor according to claim 1 , comprising killed bacteria of said strain.

3. A capillary disorder improving agent for improving diabetic capillary disorder, comprising Enterococcus faecium strain R30.

4. The agent for improving capillary disorders according to claim 3 , comprising killed bacteria of said strain.

Images